{"id":4578,"date":"2026-09-14T10:00:43","date_gmt":"2026-09-14T08:00:43","guid":{"rendered":"https:\/\/www.fondazionebonadonna.eu\/?p=4578"},"modified":"2026-09-10T16:06:00","modified_gmt":"2026-09-10T14:06:00","slug":"daraxonrasib-in-metastatic-pancreatic-cancer","status":"publish","type":"post","link":"https:\/\/www.fondazionebonadonna.eu\/en\/daraxonrasib-in-metastatic-pancreatic-cancer\/","title":{"rendered":"Daraxonrasib in metastatic pancreatic cancer"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column][vc_custom_heading text=&#8221;The oral RAS(ON) multi-selective inhibitor daraxonrasib shows a significantly longer overall survival and progression-free survival in patients with previously treated metastatic pancreatic ductal adenocarcinoma&#8221; font_container=&#8221;tag:h3|text_align:left&#8221; use_theme_fonts=&#8221;yes&#8221;][\/vc_column][\/vc_row][vc_row][vc_column width=&#8221;1\/2&#8243;][vc_column_text]New data from the RASolute 302 trial, <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2605555\" target=\"_blank\" rel=\"noopener\">recently published on The New England Journal of Medicine<\/a>, show a significantly longer overall survival and progression-free survival with the oral RAS(ON) multi-selective inhibitor daraxonrasib in patients with previously treated metastatic pancreatic ductal adenocarcinoma (mPDAC).<\/p>\n<p>Daraxonrasib is a multi-selective inhibitor of RAS(ON) proteins and the first investigational agent in a novel class of RAS inhibitors designed to address a diverse and broad spectrum of oncogenic RAS drivers: more than 90% of patients with pancreatic cancer harbor tumors driven by mutations in RAS proteins. The RASolute 302 trial is a phase 3, international, open-label, randomized trial involving 500 patients (91.8% with RAS G12 mutations) randomly assigned to receive daraxonrasib or chemotherapy. The median overall survival in the <em>RAS<\/em> G12 population was 13.2 months with daraxonrasib and 6.6 months with chemotherapy, and the median overall survival in the overall population was 13.2 months and 6.7 months, respectively; the median progression-free survival in the <em>RAS<\/em> G12 population was 7.3 months with daraxonrasib and 3.5 months with chemotherapy, and that in the overall population was 7.2 months and 3.6 months, respectively. Treatment-related adverse events that led to treatment discontinuation occurred in 1.2% of the patients in the daraxonrasib group and in 11.2% of those in the chemotherapy group. As principal investigator and director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute Brian M. Wolpin stated, \u00abFor patients with metastatic pancreatic cancer, new treatment options are urgently needed to increase survival time and improve quality of life. Daraxonrasib provides a clear and highly meaningful step forward for patients with pancreatic cancer who have experienced progression on prior treatment, typically chemotherapy\u00bb.[\/vc_column_text][\/vc_column][vc_column width=&#8221;1\/2&#8243;][vc_single_image image=&#8221;4581&#8243; img_size=&#8221;large&#8221;][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_custom_heading text=&#8221;The oral RAS(ON) multi-selective inhibitor daraxonrasib shows a significantly longer overall survival and progression-free survival in patients with previously treated metastatic pancreatic ductal adenocarcinoma&#8221; font_container=&#8221;tag:h3|text_align:left&#8221;<span class=\"excerpt-hellip\"> [\u2026]<\/span><\/p>\n","protected":false},"author":2,"featured_media":4581,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[39,21],"tags":[],"class_list":["post-4578","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-events","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Daraxonrasib in metastatic pancreatic cancer - Fondazione Gianni Bonadonna<\/title>\n<meta name=\"description\" content=\"The oral RAS(ON) multi-selective inhibitor daraxonrasib shows a significantly longer overall survival and progression-free survival in patients with previously treated metastatic pancreatic ductal adenocarcinoma\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fondazionebonadonna.eu\/en\/daraxonrasib-in-metastatic-pancreatic-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Daraxonrasib in metastatic pancreatic cancer - Fondazione Gianni Bonadonna\" \/>\n<meta property=\"og:description\" content=\"The oral RAS(ON) multi-selective inhibitor daraxonrasib shows a significantly longer overall survival and progression-free survival in patients with previously treated metastatic pancreatic ductal adenocarcinoma\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fondazionebonadonna.eu\/en\/daraxonrasib-in-metastatic-pancreatic-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Fondazione Gianni Bonadonna\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-14T08:00:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2026\/09\/Image_nejm_14Sep26-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1215\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fondazione Gianni Bonadonna\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fondazione Gianni Bonadonna\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/daraxonrasib-in-metastatic-pancreatic-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/daraxonrasib-in-metastatic-pancreatic-cancer\\\/\"},\"author\":{\"name\":\"Fondazione Gianni Bonadonna\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\"},\"headline\":\"Daraxonrasib in metastatic pancreatic cancer\",\"datePublished\":\"2026-09-14T08:00:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/daraxonrasib-in-metastatic-pancreatic-cancer\\\/\"},\"wordCount\":343,\"image\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/daraxonrasib-in-metastatic-pancreatic-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/Image_nejm_14Sep26-scaled.jpg\",\"articleSection\":[\"Events\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/daraxonrasib-in-metastatic-pancreatic-cancer\\\/\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/daraxonrasib-in-metastatic-pancreatic-cancer\\\/\",\"name\":\"Daraxonrasib in metastatic pancreatic cancer - Fondazione Gianni Bonadonna\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/daraxonrasib-in-metastatic-pancreatic-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/daraxonrasib-in-metastatic-pancreatic-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/Image_nejm_14Sep26-scaled.jpg\",\"datePublished\":\"2026-09-14T08:00:43+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\"},\"description\":\"The oral RAS(ON) multi-selective inhibitor daraxonrasib shows a significantly longer overall survival and progression-free survival in patients with previously treated metastatic pancreatic ductal adenocarcinoma\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/daraxonrasib-in-metastatic-pancreatic-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/daraxonrasib-in-metastatic-pancreatic-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/daraxonrasib-in-metastatic-pancreatic-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/Image_nejm_14Sep26-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/Image_nejm_14Sep26-scaled.jpg\",\"width\":2560,\"height\":1215},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/daraxonrasib-in-metastatic-pancreatic-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Daraxonrasib in metastatic pancreatic cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#website\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/\",\"name\":\"Fondazione Gianni Bonadonna\",\"description\":\"Fondazione Gianni Bonadonna\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\",\"name\":\"Fondazione Gianni Bonadonna\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"caption\":\"Fondazione Gianni Bonadonna\"},\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/author\\\/fgb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Daraxonrasib in metastatic pancreatic cancer - Fondazione Gianni Bonadonna","description":"The oral RAS(ON) multi-selective inhibitor daraxonrasib shows a significantly longer overall survival and progression-free survival in patients with previously treated metastatic pancreatic ductal adenocarcinoma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fondazionebonadonna.eu\/en\/daraxonrasib-in-metastatic-pancreatic-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Daraxonrasib in metastatic pancreatic cancer - Fondazione Gianni Bonadonna","og_description":"The oral RAS(ON) multi-selective inhibitor daraxonrasib shows a significantly longer overall survival and progression-free survival in patients with previously treated metastatic pancreatic ductal adenocarcinoma","og_url":"https:\/\/www.fondazionebonadonna.eu\/en\/daraxonrasib-in-metastatic-pancreatic-cancer\/","og_site_name":"Fondazione Gianni Bonadonna","article_published_time":"2026-09-14T08:00:43+00:00","og_image":[{"width":2560,"height":1215,"url":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2026\/09\/Image_nejm_14Sep26-scaled.jpg","type":"image\/jpeg"}],"author":"Fondazione Gianni Bonadonna","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fondazione Gianni Bonadonna","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/daraxonrasib-in-metastatic-pancreatic-cancer\/#article","isPartOf":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/daraxonrasib-in-metastatic-pancreatic-cancer\/"},"author":{"name":"Fondazione Gianni Bonadonna","@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146"},"headline":"Daraxonrasib in metastatic pancreatic cancer","datePublished":"2026-09-14T08:00:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/daraxonrasib-in-metastatic-pancreatic-cancer\/"},"wordCount":343,"image":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/daraxonrasib-in-metastatic-pancreatic-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2026\/09\/Image_nejm_14Sep26-scaled.jpg","articleSection":["Events"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/daraxonrasib-in-metastatic-pancreatic-cancer\/","url":"https:\/\/www.fondazionebonadonna.eu\/en\/daraxonrasib-in-metastatic-pancreatic-cancer\/","name":"Daraxonrasib in metastatic pancreatic cancer - Fondazione Gianni Bonadonna","isPartOf":{"@id":"https:\/\/www.fondazionebonadonna.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/daraxonrasib-in-metastatic-pancreatic-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/daraxonrasib-in-metastatic-pancreatic-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2026\/09\/Image_nejm_14Sep26-scaled.jpg","datePublished":"2026-09-14T08:00:43+00:00","author":{"@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146"},"description":"The oral RAS(ON) multi-selective inhibitor daraxonrasib shows a significantly longer overall survival and progression-free survival in patients with previously treated metastatic pancreatic ductal adenocarcinoma","breadcrumb":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/daraxonrasib-in-metastatic-pancreatic-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fondazionebonadonna.eu\/en\/daraxonrasib-in-metastatic-pancreatic-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/daraxonrasib-in-metastatic-pancreatic-cancer\/#primaryimage","url":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2026\/09\/Image_nejm_14Sep26-scaled.jpg","contentUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2026\/09\/Image_nejm_14Sep26-scaled.jpg","width":2560,"height":1215},{"@type":"BreadcrumbList","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/daraxonrasib-in-metastatic-pancreatic-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fondazionebonadonna.eu\/en\/"},{"@type":"ListItem","position":2,"name":"Daraxonrasib in metastatic pancreatic cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.fondazionebonadonna.eu\/#website","url":"https:\/\/www.fondazionebonadonna.eu\/","name":"Fondazione Gianni Bonadonna","description":"Fondazione Gianni Bonadonna","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fondazionebonadonna.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146","name":"Fondazione Gianni Bonadonna","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","caption":"Fondazione Gianni Bonadonna"},"url":"https:\/\/www.fondazionebonadonna.eu\/en\/author\/fgb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts\/4578","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/comments?post=4578"}],"version-history":[{"count":4,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts\/4578\/revisions"}],"predecessor-version":[{"id":4587,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts\/4578\/revisions\/4587"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/media\/4581"}],"wp:attachment":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/media?parent=4578"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/categories?post=4578"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/tags?post=4578"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}